The FDA on December 22, 2022 granted accelerated approval to LUNSUMIO®, a bispecific CD20-directed CD3 T-cell engager for adult patients with Relapsed or Refractory Follicular Lymphoma (FL) after two or more lines of systemic therapy. LUNSUMIO® is a product of Genentech, Inc.
Other Pages – Bottom Ad
Advertisement
Subscribe
